Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
April 29, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00...
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
April 29, 2024 07:00 ET
|
George Medicines
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
April 29, 2024 06:45 ET
|
Ocugen
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
April 29, 2024 06:05 ET
|
MannKind
MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START PHASE 3 STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NTM LUNG DISEASE
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 09:05 ET
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
April 25, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination
April 25, 2024 08:00 ET
|
SDS Optic S.A.
SDS Optic's positive results from the Part I Clinical Trial of the novel optic fiber probe, inPROBE®, in vivo real-time molecular diagnostic technology.
Global Bionic Devices Industry Research, 2023-2024 & 2030: Addressing Diverse Healthcare Needs Worldwide to Sustain Growth and Fuel Develoments
April 25, 2024 05:29 ET
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Global Bionic Devices Market, By Product, By Fixation, By Technology, By End User, Country Wise Market Analysis, Key Company Profiles, Trends and...
Cytokinetics to Announce First Quarter Results on May 8, 2024
April 24, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00...